Twist Bioscience Corp (TWST) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Twist Bioscience Corp stock (TWST) is currently trading at $48.64. Twist Bioscience Corp PS ratio (Price-to-Sales) is 7.44. Analyst consensus price target for TWST is $49.89. WallStSmart rates TWST as Sell.
- TWST PE ratio analysis and historical PE chart
- TWST PS ratio (Price-to-Sales) history and trend
- TWST intrinsic value — DCF, Graham Number, EPV models
- TWST stock price prediction 2025 2026 2027 2028 2029 2030
- TWST fair value vs current price
- TWST insider transactions and insider buying
- Is TWST undervalued or overvalued?
- Twist Bioscience Corp financial analysis — revenue, earnings, cash flow
- TWST Piotroski F-Score and Altman Z-Score
- TWST analyst price target and Smart Rating
Twist Bioscience Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Twist Bioscience Corp (TWST) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Twist Bioscience Corp (TWST) Key Strengths (2)
122.67% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Twist Bioscience Corp (TWST) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 5.7x book value
Premium valuation at 7.4x annual revenue
Solid revenue growth at 16.90% per year
Supporting Valuation Data
Twist Bioscience Corp (TWST) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (7.44), Price/Book (5.66) suggest expensive pricing. Growth concerns include Revenue Growth at 16.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.80%, Operating Margin at -31.70%, Profit Margin at -19.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 16.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TWST Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TWST's Price-to-Sales ratio of 7.44x trades at a deep discount to its historical average of 30.3x (25th percentile). The current valuation is 93% below its historical high of 111.97x set in Jan 2021, and 98% above its historical low of 3.76x in Apr 2023.
Compare TWST with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Twist Bioscience Corp (TWST) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Twist Bioscience Corp is a strong growth company balancing expansion with improving profitability. Revenue reached 392M with 17% growth year-over-year. The company is currently unprofitable, posting a -19.6% profit margin.
Key Findings
The company is unprofitable with a -19.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -35M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.29, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Twist Bioscience Corp.
Bottom Line
Twist Bioscience Corp offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Twist Bioscience Corp(TWST)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.